Increasing avß3 selectivity of the anti-angiogenic drug cilengitide by N-methylation by Mas Moruno, Carlos et al.
Supporting Information
 Wiley-VCH 2011
69451 Weinheim, Germany
Increasing avb3 Selectivity of the Anti-Angiogenic Drug Cilengitide by
N-Methylation**
Carlos Mas-Moruno, Johannes G. Beck, Lucas Doedens, Andreas O. Frank, Luciana Marinelli,
Sandro Cosconati, Ettore Novellino, and Horst Kessler*
anie_201102971_sm_miscellaneous_information.pdf
S1 
SUPPORTING INFORMATION 
 
       
TABLE OF CONTENTS 
1. List of abbreviations        S2 
2. Solid-phase peptide synthesis       S3 
3. Table S1. Synthesis and characterization of the peptides    S6 
4. NMR spectroscopy         S7 
5. Structure calculations for peptides 1, 4 and 10     S9 
6. Molecular modeling        S17 
7. Competitive solid-phase integrin binding assay     S19 
8. Figures S1 and S2         S21 
9. HPLC chromatograms and HRMS spectra of all peptides    S22 
10. Full citation list         S32 
11. References          S32 
 
 
 
 
 
 
1. List of abbreviations. 
 
DBU:  1,8-Diazabicyclo-[5.4.0]undec-7-ene 
DCM:   Dichloromethane 
DIAD:  Diisopropyl azodicarboxylate  
DIEA:  N,N-Diisopropylethylamine 
DMF:  N,N-Dimethylformamide 
DPPA:  Diphenylphosphonic acid azide 
Fmoc  9-Fluorenylmethoxycarbonyl 
S2 
HATU  N-[(Dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridino-1-ylmethylene]-N- 
methylmethanaminium hexafluorophosphate 
HFIP  Hexafluoroisopropanol  
HOAt:  1-Hydroxy-7-azabenzotriazole 
HOBT  1-Hydroxybenzotriazole 
HPLC:  High-performance liquid chromatography 
HRMS: High-resolution mass spectrometry 
MS:  Mass spectrometry 
NMP:  N-Methyl-2-pyrrolidon  
NMR:  Nuclear magnetic resonance 
o-NBS: o-Nitrobenzenesulfonyl chloride  
Pbf:  2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl group 
TBTU N-[(1H-Benzotriazol-1-yl)-dimethylamino-methylene]-N-methylmethanaminium 
tetrafluoroborate N-oxide 
TCP:  Trityl chloride polystyrene resin 
TFA   Trifluoroacetic acid 
THF  Tetrahydrofuran  
TIS:  Triisopropylsilane  
 
Abbreviations used for amino acids and the designations of peptides follow the rules of the IUPAC-IUB 
Commission of Biochemical Nomenclature in J. Biol. Chem. 1989, 264, 668–673. Amino acid symbols 
denote the L configuration unless otherwise stated.  
 
 
2. Solid-phase peptide synthesis. 
 
2.1 Chemicals and instrumentation 
Protected Fmoc-amino acids and coupling reagents were purchased from Novabiochem (Schwalbach, 
Germany), Iris Biotech GmbH (Marktredwitz, Germany) and Medalchemy (Alicante, Spain). TCP resin 
was obtained from Pepchem (Tübingen, Germany). All other chemicals and organic solvents were 
purchased from commercial suppliers at the highest purity available and used without further purification. 
Analytical HPLC was performed using an Amersham Pharmacia Biotech Äkta Basic 10F equipment, 
with a P-900 pump system, a reversed-phase YMC-ODS-A C18 column (4.6 ´ 250 mm, 5 mm), and UV 
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detection (UV-900, 220 and 254 nm). The system was run at a flow rate of 1.0 mL/min over 30 min 
using H2O (0.1% TFA) and MeCN (0.1% TFA) as solvents. HPLC-MS analyses were performed on a 
Hewlett Packard Series HP 1100 with a Finnigan LCQ mass spectrometer using a YMC-Hydrosphere 
C18 column (2.1 ´125 mm, 3 mm). The system was run at a flow rate of 0.2 mL/min over 15 min using 
H2O (0.1% formic acid) and MeCN (0.1% formic acid) as eluents. Semi-preparative HPLC was carried 
out on a Beckmann instrument (system gold, solvent delivery module 126, UV detector 166) using an 
YMC ODS-A column (20 ´ 250 mm, 5 mm), with a flow rate of 8 mL/min. Linear gradients using H2O 
(0.1% TFA) and MeCN (0.1% TFA) were run over varying periods of time. HRMS were recorded on a 
Thermo Finnigan LTQ-FT (ESI-ICR) spectrometer.   
 
2.2 General 
The peptides were manually synthesized in solid-phase using the Fmoc strategy and TCP resin as solid 
support following protocols previously described in the literature [1].  Solvents and soluble reagents 
were removed by suction. Washings between deprotection, couplings, and subsequent deprotection steps 
were carried out with NMP and DCM, using 10 mL of solvent/g of resin each time. All reactions and 
treatments were performed at room temperature. Couplings were monitored using Kaiser or chloranil 
methods [2] and by HPLC and/or ESI-MS analysis. 
 
2.3 Protocols 
 
Loading of the resin 
Fmoc-Xaa-OH (1.2 equiv) and DIEA (3 equiv) dissolved in anhydrous DCM were sequentially added to 
TCP resin (200 mg, 0.95 mmol/g) and the resin was stirred for 1 h. The incorporation was followed by a 
capping step with MeOH (1 mL/g resin) and DIEA (0.2 mL/g resin) for 15 min. Next, the resin was 
washed thoroughly with DCM (3×), NMP (3×), NMP-MeOH (1:1) (3×) and MeOH (3×). The loading 
capacity was determined by weight after drying the resin under vacuum, and ranged from 0.6 to 0.9 
mmol/g. 
 
Fmoc group removal 
The Fmoc group was removed by treatment with piperidine-NMP (1:4, v/v) for 2 × 10 min. After this 
treatment the resin was washed with NMP (3×), DCM (3×) and NMP (3×).  
 
Amino acid coupling 
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Amide bond formation was typically carried out coupling the pre-activated ester of each amino acid to 
the free resin-bound amine. Fmoc-Xaa-OH (3 equiv) was dissolved in NMP in the presence of TBTU (3 
equiv), HOBt (3 equiv) and DIEA (6 equiv). Subsequently this mixture was added to the resin and 
shaken for 2 to 3 h. Incorporation of amino acids over resin-bound N-a methylamine free peptides was 
more demanding. In this case, Fmoc-Xaa-OH (3 equiv) were coupled for 1 to 2 h using HATU (3 equiv), 
HOAt (3 equiv) and DIEA (6 equiv) in NMP as coupling system. One of the most challenging couplings 
was the insertion of Fmoc-NMeVal-OH over the bulky NMeArg(Pbf)-peptidyl resin, for which 3 
recouplings were required with HATU to ensure complete conversion.  
 
N-a acetylation 
Whenever a quantitative yield was not achieved even after recoupling treatments, the free N-a amino 
group was acetylated with Ac2O-DIEA-NMP (1:2:7, v/v/v) for 1 × 1 min, 1 × 5 min. 
 
N-a methylation 
On resin N-methylation of the free N-a amino groups was done as described elsewhere [3]. First, the N-
terminal N-a primary amines were protected with o-nitrobenzenesulfonyl chloride (o-NBS) (5 equiv) in 
the presence of collidine (10 equiv) in NMP for 10 min. After washing the resin with NMP (3×) and THF 
(3×), the methylation was done under Mitsunobu conditions treating the resin with triphenylphosphine (5 
equiv), anhydrous MeOH (10 equiv) and DIAD (5 equiv) in THF for 10 min. Next, the resin was washed 
with THF (3×) and NMP (3×) and finally treated with 2-mercaptoethanol (10 equiv) and DBU (5 equiv) 
in NMP (2 × 5 min) in order to remove the o-NBS group. This methodology was applied to N-methylate 
Arg and Asp. Fmoc-Val-OH and Fmoc-D-Phe-OH were N-methylated in solution following the two-step 
procedure described by Freidinger [4] (condensation of the Fmoc-protected amino acid with 
paraformaldehyde to form the corresponding oxazolidinone followed by reduction with triethylsilane and 
TFA).   
 
Cleavage from the resin   
The protected resin bound linear pentapeptides were cleaved from the resin using HFIP-DCM (1:4, v/v) 
for 2 ´ 45 min, 1 ´ 1 min. The solvents were evaporated and the crude product redissolved in 
H2O-MeCN (1:1, v/v) and lyophilized.  
 
Peptide cyclization  
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Two methods were used for the head-to-tail cyclization of the protected linear peptides. Method A: The 
side chain protected peptide was dissolved in anhydrous DMF at a 1 mM concentration. Next, NaHCO3 
(5 equiv) and DPPA (3 eqiuv) were added and the mixture stirred overnight at room temperature. The 
reaction was monitored by HPLC and ESI-MS. After reaction completion, the DMF was evaporated in 
vaccuo (keeping a temperature lower than 50 °C). The residue was redissolved in 1-2 mL of DMF and 
transferred to a 50-mL falcon tube containing ~ 40 mL of cold H2O-brine (1:1, v/v). The precipitated 
peptide was obtained as a white suspension. After centrifugation and washing with cold H2O (´ 2) the 
solid was dried in vaccuo. Method B: To a vigorously stirred solution of the linear peptide in DMF was 
added dropwise a solution of HATU (1.5 equiv), HOBt (1.5 equiv) and collidine (1.5 equiv) in DMF, 
making a final concentration of 1 mM of the linear peptide. The solution was stirred for 2 h at room 
temperature. After DMF evaporation, a saturated solution of NaHCO3 was added to the crude product, 
which was extracted with EtOAc (´ 3). The organic phase was washed with brine and dried with 
Na2SO4. After evaporation of the organic phase, the cyclic peptide was obtained free of cyclization 
reagents.   
 
Deprotection of the cyclic peptides   
Side chain deprotection of the cyclic peptides was accomplished after treatment with distinct TFA 
mixtures. Both the amount of TFA and reaction time had to be fine tuned in order to completely remove 
the Pbf group while minimizing peptide fragmentation. [Condition A: TFA-H2O–TIS–DCM 
(60:2.5:2.5:35, v/v/v/v) for 3 h. Condition B: TFA-H2O–TIS–DCM (47.5:2.5:2.5:47.5) for 2 h. 
Condition C: TFA-H2O–TIS–DCM (60:2.5:2.5:35) for 35 min]. The unprotected peptides were then 
precipitated with cold anhydrous Et2O for 30 min, centrifuged and washed twice with ether. The 
molecules were finally redissolved in H2O-MeCN (1:1, v/v), lyophilized and purified by semi-preparative 
HPLC to purities > 95 %.  
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3. Table S1. Synthesis and characterization of the peptides 
 
Sequencea Amino acid loaded to 
the resin 
Cyc. 
Meth.b 
Dep. 
Cond.c 
HPLC 
tR (min)d 
HPLC-MS 
tR (min)e 
HRMSf  
(M+H)+ 
1   c(-R-G-D-f-V-) Fmoc-NMe-Val-OH B B 19.09 4.69 603.32241 
2   c(-R-G-D-f-V-) Fmoc-Gly-OH A A 18.22 4.47 603.32209 
3   c(-R-G-D-f-V-) Fmoc-NMe-Val-OH B A 19.15 4.78 603.32175 
4   c(-R-G-D-f-V-) Fmoc-Gly-OH A A 18.98 4.79 603.32187 
5   c(-R-G-D-f-V-) Fmoc-Arg(Pbf)-OH A A 18.55 4.52 603.32437 
6   c(-R-G-D-f-V-) Fmoc-Val-OH B B 17.97 4.27 603.32429 
7   c(-R-G-D-f-V-) Fmoc-Val-OH A A 17.42 4.15 603.32355 
8   c(-R-G-D-f-V-) Fmoc-D-Phe-OH A C 18.82 4.49 603.32253 
9   c(-R-G-D-f-V-) Fmoc-Val-OH A A 18.97 4.55 603.32365 
10 c(-R-G-D-f-V-) Fmoc-Gly-OH A A 19.59 4.80 603.32275 
 
 
a N-methylated amino acids are highlighted in grey. f = D-Phe 
b Cyclization methods A and B are described in section 2.3 
c Side chain deprotection conditions A, B and C are described in section 2.3. 
d tR: Retention time of the purified peptides by analytical HPLC  
(linear gradient, 10 to 50 % MeCN over 30 min) 
e tR: Retention time of the purified peptides by HPLC-MS  
(linear gradient, 10 to 50 % MeCN over 15 min) 
f Calculated m/z for C28H42N8O7 602.32.  
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4. NMR Spectroscopy  
 
1D 1H NMR, E.COSY, TOCSY, ROESY, 13C-HMBC, 13C-HSQC, and 15N-HETLOC were recorded at 
300 K on a Bruker Avance III spectrometer operating at 500 MHz. Samples were prepared in DMSO-d6 
at concentrations of 42 mM (1), 46 mM (10) and 80 mM (4) in 3 mm NMR tubes. DMSO-d6 (1H at 2.52 
ppm, 13C at 40.45 ppm) was used as internal standard. Data were processed with Topspin 1.3 software 
from Bruker. The homo- and heteronuclear experiments E.COSY, TOCSY, HSQC, and magnitude mode 
13C-HMBC were recorded with a spectral width of 13 ppm for 1H. HSQC and magnitude mode 13C-
HMBC were recorded with a spectral width of 160 ppm and 200 ppm for 13C, respectively. ROESY 
spectra were recorded with spectral widths of 8.2 ppm (1, 10) and 10.8 ppm (4). 15N filtered 2D TOCSY 
experiments (15N-HETLOC) [5, 6] were set up as described by Uhrín et al. [7] and recorded with 
spectral widths of 8.4 ppm (1) and 8.8 ppm (10) for 1H. The increments in t1 and t2 were adjusted to the 
information extracted from the individual experiments, ranging from 192 to 2048 increments in t1 and 
from 1024 to 32768 complex data points in t2. Depending on the individual experiments, 8 to 72 
transients were averaged for each t1 value. A mixing time of 80 ms was used for TOCSY (spin lock field: 
6.25 kHz; mixing sequence DIPSI2). The sequential assignments were obtained from heteronuclear J 
correlations that were extracted from HSQC and HMBC spectra. Compensated ROESY experiments, 
which were used for the extraction of inter proton distances, were performed with 100 ms mixing time 
and with spin lock fields of 4 kHz [8]. The spin lock was achieved using a train of 15° pulses. The 
volume integrals of the individually assigned cross-peaks were compensated for offset effects and 
converted into distance constraints using the isolated spin pair approximation [9]. The ROESY cross-
peak volumes were calibrated against the distance between the Val5 Hg protons (1), against the distance 
(2.41 Å) between the Val Ha and Hb protons (10) and against the distance (1.8 Å) between the Arg1 Hb 
protons (4). For 1 the bounds obtained that way turned out to be too short and were thus stretched by 15 
%; a procedure that was justified by significant overlap of the cross peaks with edges of the diagonal 
peaks and by possible TOCSY transfer, which may have diminished the cross peak volumes. Upper and 
lower distance limits were set to plus and minus 10 % of the calculated distances, respectively. For 
distance restraints referring to degenerate protons, the numbers n1 and n2 of the involved degenerate 
target protons were considered by multiplying the upper and lower bounds with a factor of (n1n2)1/6 as 
multiplicity correction [10]. 0.4 Å were added on upper bounds as pseudoatom corrections for restraints 
referring to a methyl group. 0.8 Å were added on upper bounds as pseudoatom corrections for ROEs 
between two methyl groups. 8 intraresidual, 10 sequential interresidual and 1 non-sequential interresidual 
ROE derived distance restraints were used for structure calculations of 1. Another 3 sequential 
interresidual and 1 non-sequential interresidual ROEs were used for MD trajectory analysis. 7 
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intraresidual, 12 sequential interresidual and 3 non-sequential interresidual ROE derived distance 
restraints were used for structure calculations of 4. 10 intraresidual, 7 sequential interresidual and 3 non-
sequential interresidual ROE derived distance restraints were used for structure calculations of 10. 
Another 7 sequential interresidual ROEs were used for MD trajectory analysis. Restraints between 
residues 1 and 5 were counted as sequential. 
3JHN-Ha coupling constants were determined from 1D 1H NMR spectra and 3JHa-Hb coupling constants 
from E.COSY. 3JN-Hb coupling constants were obtained from 15N-HETLOC spectra by reading the f2 
splitting of (E.COSY type) HN-Hb crosspeaks. 
Table S2: Resonance assignment of 1, 4 and 10 in DMSO-d6 at 300 K. Chemical shifts are referenced on 
DMSO (1H at 2.520 ppm). (R) and (S) designate proR and proS prochiral protons or methyl groups. 
 
1 HN (HMe) Ha Hb Hg Hd He H? 
Arg1 8.345 3.539 1.96 1.467 3.11 7.558  
Gly2 7.593 3.592 / 4.148      
NMe-Asp3 (2.834) 4.638 2.398 / 2.920     
D-Phe4 8.07 5.011 2.764 (S) / 3.092 (R)  7.189 7.243 7.173 
NMe-Val5 (2.859) 4.327 2.056 0.540 (S) / 0.867 (R)    
        
4 HN (HMe) Ha Hb Hg Hd He H? 
NMe-Arg1 (2.603) 4.732 1.689 / 2.069 1.350 / 1.475 3.160 7.610  
Gly2 8.256 3.395 / 3.740      
Asp3 8.670 4.661 2.452 (S) / 2.822 (R)     
D-Phe4 7.459 4.990 2.852 (S) /2.917 (R)  7.183 7.253 7.200 
NMe-Val5 (2.749) 4.854 2.121 0.342 (S) / 0.731 (R)    
        
10 HN (HMe) Ha Hb Hg Hd He H? 
NMe-Arg1 (3.227) 3.707 1.838 / 2.022 1.401 / 1.582 3.145 7.591  
Gly2 8.334 3.331 / 4.099      
Asp3 7.217 4.879 2.295 (S) / 2.723 (R)     
NMe-D-Phe4 (2.667) 5.502 2.944 / 3.199  7.222 7.273 7.211 
Val5 6.805 4.751 2.015 0.683 (R) / 0.912 (S)    
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5. Structure calculations for peptides 1, 4 and 10  
The structural NMR refinement protocol included distance geometry (DG) calculations and energy 
minimization in explicit DMSO. Molecular dynamics (MD) simulations were used in order to obtain 
additional information about the dynamics of the peptides. The DG program DISGEO was used to 
generate structures consistent with the distance restraints derived from the ROEs [11, 12]. The DG 
procedure included the embedding of 49 structures of the three peptides under investigation using 
random metrization. The structures obtained from DG were evaluated according to the lowest total 
restraint violations. The conformers with the lowest restraint violations were refined by energy 
minimization in explicit DMSO and further analyzed by MD simulation in explicit DMSO. 
The GROMACS 4.0 software package (www.gromacs.org) [13-15] was used to perform energy 
minimizations and unrestrained MD calculations. Visualization of the simulation trajectories was 
performed using the software packages VMD [16] and SYBYL. The scripts g_cluster, g_dist and 
g_angle, that were used for analysis of the MD trajectory, were all packaged with GROMACS. The 53a6 
united atom (CH, CH2 and CH3 groups represented as a single atom) forcefield, one of the GROMOS96 
force fields [17], was used for the molecular dynamic simulations. Temperature and pressure control was 
executed by Berendsen coupling [18]. Periodic boundary conditions were employed on a octahedral 
simulation box, which was built with a distance of 2 nm for the solute, that consisted of more than 1200 
DMSO molecules. Cut off distances of 1.4 nm for electrostatic and Lennard-Jones non-bonding 
interactions were applied. Simulation time steps were set to 2 fs.  
Energy minimization in vacuo 
Energy minimizations were applied to avoid geometry distortions like lacking planarity of peptide bonds 
in order to prepare DG conformations for docking. Steepest descent energy minimization was performed 
until the biggest force was smaller than 1000 KJ mol-1nm-1. Any strong structural change (as induced by 
the formation of salt bridges) was avoided using weak position restraints of 250 – 2500 KJmol-1nm-2. 
Energy minimization in explicit solvent 
Energy minimization in explicit DMSO was performed after careful equilibration of the surrounding 
solvent, which was ensured by subsequent MD simulations at a series of different temperatures of 50, 
100, 150, 200, 250, 300, 250, 200, 150, 100 and 50 K. At every step 20 ps temperature equilibration and 
20 ps pressure equilibration were performed. Position restraints of 250000 KJmol-1nm-2 were employed 
on the peptide atoms at all these steps until the temperature was decreased back to 150 K. For the last 
two temperature steps at 100 K and 50 K, position restraints were reduced to 25000 KJmol-1nm-2 and 
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2500 KJmol-1nm-2, respectively. The final steepest descent energy minimization was run without position 
restraints and stopped as soon as the biggest force was smaller than 100 KJmol-1nm-1. 
MD simulation 
Preparation for MD simulations was similar but slightly different: the system was equilibrated by an initial 
minimization and subsequent 50 ps MD simulations at 50, 100, 150, 200, 250 and 300 K using position 
restraints. At every single temperature a temperature and a pressure equilibration was performed. Within 
the individual MD steps, the temperature was gradually increased, while the force constants of the 
position restraints were decreased exponentially from 250000 KJmol-1nm-2 at 50 K to 25 KJmol-1nm-2 at 
250° K. At 300 K no position restraints were applied. The final 50 ns (1 and 4) and 100 ns (10) MD 
simulations were carried out at 300 K. Coordinates were saved every 10 ps. For analyzing the quality of 
the MD runs, apparent inter-proton distances were back calculated (equation S1) from 1001 
conformations that were extracted at intervals of 50 ps (1 and 4) and of 100 ps (10). 
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rframe was calculated for the frames of the trajectories for every single internuclear distance under 
consideration. A self written perl script was used for this purpose. It extracted the coordinates from the 
frames, calculated the distances and performed r-6 based averaging of the individual distances resulting in 
rapp (equation S1). 
Consistency between experimental and back calculated ROEs could be improved to the values shown in 
Tables S4 and S5 by adding few conformational constraints to the final MD simulations of 1 and 4. For 
1, NMe-Asp3 ?  and D-Phe4 F  were restrained to 82° and 120°, respectively (D-Phe4 3JHN-Ha = 9.3 Hz). 
For 4, Gly2 ?  and Asp3 F  were restrained to -45° and -120°, respectively (Asp3 3JHN-Ha = 9.0 Hz). 
Additionally, a time averaged distance restraint was applied to keep NMe-Arg1 Ca and D-Phe4 HN 
between 3.3 and 4.1 Å (the ROE between NMe-Arg1 Ha and D-Phe4 HN suggests 3.15 to 3.84 Å). 
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Preferred Conformations 
Table S3: F  and ?  dihedral angles of 1, 4 and 10 as derived by DG calculation and subsequent energy 
minimization. 
1 F MD [°] ? MD [°] 
Arg1 66.6 83.0 
Gly2 80.2 152.2 
NMe-Asp3 -8.9 100.2 
D-Phe4 99.1 -110.7 
NMe-Val5 -115.8 116.6 
   
4 F MD [°] ? MD [°] 
NMe-Arg1 -114.7 -157.5 
Gly2 88.9 -106.0 
Asp3 -109.4 58.7 
D-Phe4 158.2 -97.6 
NMe-Val5 -149.0 76.9 
   
10 F MD [°] ? MD [°] 
NMe-Arg1 114.5 164.2 
Gly2 -47.5 -35 
Asp3 -90.4 98.9 
NMe-D-Phe4 79.8 -95.1 
Val5 -121.5 87.1 
 
In peptide 1, all peptide bonds are in trans configuration and all peptide bond planes, except of the Gly2-
NMe-Asp3 peptide bond are oriented almost perpendicular to the plane of the peptide ring (Figure 2). 
Characteristic dihedral angles for complete b- and g-turns are missing. The C-O bond vectors of Arg1, 
NMe-Asp3 and D-Phe4 are aligned parallel with respect to Ca-Ha bond vectors of the respective 
subsequent residue. Antiparallel orientations of these dipolar bonds are crucial for stabilizing peptide 
conformations [19]. Two similar ROEs between NMe-Asp3 HMe and both Gly2 a  protons (Table S4) 
clearly support the Gly2-NMe-Asp3 peptide bond to be in plane with the peptide ring. Extended 50 ns 
MD simulation in explicit DMSO further indicated significant flexibility of the Gly residue and the 
adjacent peptide bonds. 
According to the backbone dihedral angles of NMe-Val5 (F =-121.5°, ? =87.1°), NMe-Arg1 (F =-114.5°, 
? =164.2°) and an intermediary cis configured peptide bond, 4 possesses a b-turn of type VIb along these 
residues (Figure 2). A strongly negative temperature gradient of Gly2 HN (-5.04 ppb/K in DMSO) 
indicates that the turn is not stabilized by a hydrogen bond. Asp3 is located in position i+1 of an inverted 
g-turn. Asp3 F =-90.4° and Asp3 ? =90.9° suggest a weak hydrogen bond between Gly2 O’ and D-Phe4 
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HN, that is also supported by protection of D-Phe4 HN from the solvent (d = 7.459 ppm; Dd/DT = -2.34 
ppb/K). The C-O bond vectors of NMe-Arg1, Gly2, Asp3 and D-Phe4 are aligned parallel with respect to 
Ca-Ha bond vectors of the respective subsequent residue. Extended 50 ns MD simulation in explicit 
DMSO indicated significant flexibility of the NMe-Arg1-Gly2 and the Asp3-D-Phe4 substructures. 
A g turn centered at NMe-D-Phe4 (F  = 79.8°, ?  = -95.1°) with a characteristic strong hydrogen bond 
between Asp3 O’ and Val5 HN (d = 6.805 ppm; Dd/DT = 0.53 ppb/K) is found in 10. No further b- and g-
turns are present. The C-O bond vectors of Gly2, Asp3 and NMe-D-Phe4 are aligned parallel with respect 
to Ca-Ha bond vectors of the respective subsequent residue. Extended 50 ns MD simulation in explicit 
DMSO indicated significant flexibility of the Arg1-Gly2 substructures. There is no experimental evidence 
for the salt bridge that seems to be formed between the Arg and Asp side chains according to Figure 2. 
Energy minimization (in explicit DMSO) of two different DG conformers (with identical backbone 
conformations, but different Arg and Asp side chain conformations) indicated that the backbone 
conformation shown in Figure 2 is preferred independent on whether the salt bridge is present or not. As 
the side chains were flexible during the docking process, the initial side chain conformation is not relevant 
for the docking results. 
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Table S4: Comparison between the experimentally derived distance restraints (dlow), (dupp) and calculated 
(dDG, dMD) interproton distances of compound 1 as obtained from DG calculation and unrestrained MD 
calculation (r-6 averaged distance that were backcalculated from 1001 frames of the 50 ns MD trajectory 
(dMD is equal to rapp in equation S1)). Violations of upper bounds (positive sign) and of lower bounds 
within the MD trajectory (negative sign) are also given (dviol). 
interproton distance dlow [Å] dupp [Å] dDG [Å] dMD [Å] dviol [Å]
(*) utilization(**) 
Arg1 HN Arg1 Ha 1.92 2.35 2.21 2.02  c 
Arg1 Ha Gly2 HN 2.55 3.12 2.27 3.44 +0.32 c 
Arg1 HN NMe-Val5 Ha 1.85 2.26 2.06 2.09  c 
Arg1 HN NMe-Val5 HgproR 2.96 4.01 3.56 3.53  c 
Arg1 HN NMe-Val5 HMe 3.44 4.60 4.66 4.97 +0.37 a 
Gly2 HN NMe-Asp3 HMe 3.09 4.18 4.34 3.79  c 
Gly2 Ha’ NMe-Asp3 HMe 2.66 3.65 2.41 2.48 -0.18 a 
Gly2 Ha’’ NMe-Asp3 HMe 2.66 3.65 3.22 3.81 +0.16 a 
Gly2 HN NMe-Val5 Ha 3.46 4.23 4.90 4.49 +0.26 c 
NMe-Asp3 Ha NMe-Asp3 HMe 2.68 3.67 2.57 2.54 -0.12 c 
D-Phe4 HN Gly2 Ha’ 3.74 4.57 5.64 4.95 +0.38 a 
D-Phe4 HN NMe-Asp3 Ha 2.13 2.60 2.01 2.24  c 
D-Phe4 HN NMe-Asp3 HMe 3.01 4.08 4.50 3.49  c 
D-Phe4 HN D-Phe4 Ha 2.88 3.08 2.83 2.86 -0.02 c 
D-Phe4 HN NMe-Val5 Ha 3.69 4.51 5.06 4.74 +0.23 c 
D-Phe4 Ha NMe-Val5 HgproS 3.90 5.16 4.88 4.99  c 
D-Phe4 Ha NMe-Val5 HMe 2.18 3.07 2.29 2.41  c 
NMe-Val5 HgproR Arg1 Ha 4.36 5.73 5.11 5.09  c 
NMe-Val5 HMe NMe-Val5 Hb 2.24 3.14 2.75 2.76  c 
NMe-Val5 Ha NMe-Val5 HgproR 2.54 3.51 2.75 2.98  c 
NMe-Val5 Ha NMe-Val5 HgproS 2.62 3.60 2.62 2.76  c 
NMe-Val5 HMe NMe-Val5 HgproS 3.22 4.74 3.68 3.97  c 
 
(*) Insufficient sampling of the dynamics (the length of MD simulations is limited), inaccuracy of the force fields and additional J mediated transfer 
within ROESY may explain for violations. 
 (**) Distance information used as restraints within the preceding DG calculation (c) and distance information used exclusively for the analysis (a) of 
the MD trajectory. 
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Table S5: Comparison between the experimentally derived distance restraints (dlow), (dupp) and calculated 
(dDG, dMD) interproton distances of compound 4 as obtained from DG calculation and unrestrained MD 
calculation (r-6 averaged distance that were back calculated from 1001 frames of the 50 ns MD 
trajectory), respectively. dMD is equal to rapp in equation S1. Violations of upper bounds (positive sign) 
and of lower bounds (negative sign) are also given (dviol). 
interproton distance dlow [Å] dupp [Å] dDG [Å] dMD [Å] dviol [Å]
(*) utilization(**) 
NMe-Arg1 Ha NMe-Arg1 HMe 3.53 4.72 3.33 3.59  c 
NMe-Arg1 HMe NMe-Val5 Ha 4.49 5.89 4.02 4.34 -0.15 c 
Gly2 HN NMe-Arg1 Ha 2.50 3.05 2.98 2.37 -0.13 c 
Gly2 HN NMe-Arg1 HMe 3.38 4.54 4.63 4.26  c 
Asp3 HN Gly2 HN 2.99 3.66 4.33 3.39  c 
Asp3 HN Asp3 Ha 2.42 2.96 2.88 2.81  c 
Asp3 HN D-Phe4 HN 2.95 3.61 3.28 2.78 -0.17 c 
D-Phe4 HN NMe-Arg1 Ha 3.15 3.85 3.48 4.26 +0.41 c 
D-Phe4 HN Gly2 HN 3.36 4.11 3.85 3.51  c 
D-Phe4 HN Asp3 Ha 1.98 2.42 2.55 2.49 +0.07 c 
D-Phe4 Ha NMe-Val5 HMe 2.18 3.07 2.25 2.42  c 
NMe-Val5 Ha NMe-Arg1 Ha 1.60 1.96 1.71 1.77  c 
NMe-Val5 HgproR NMe-Arg1 Ha 3.85 5.10 4.18 4.11  c 
NMe-Val5 HMe NMe-Arg1 Ha 4.58 6.00 3.54 4.61  c 
NMe-Val5 HMe Gly2 HN 4.55 5.96 5.66 5.88  c 
NMe-Val5 HMe D-Phe4 HN 4.14 5.46 3.84 4.20  c 
NMe-Val5 HgproS D-Phe4 Ha 3.13 4.22 4.30 4.89 +0.67 c 
NMe-Val5 HMe NMe-Val5 Ha 3.41 4.57 3.30 3.62  c 
NMe-Val5 HMe NMe-Val5 Hb 2.35 3.27 3.22 2.88  c 
NMe-Val5 Ha NMe-Val5 HgproS 2.23 3.13 2.84 2.87  c 
NMe-Val5 HMe NMe-Val5 HgproS 2.80 4.23 3.83 4.06  c 
NMe-Val5 Ha NMe-Val5 HgproR 2.14 3.02 2.62 2.96  c 
 
(*) Insufficient sampling of the dynamics (the length of MD simulations is limited), inaccuracy of the force fields and additional J mediated transfer 
within ROESY may explain for violations. 
 (**) Distance information used as restraints within the preceding DG calculation (c) and distance information used exclusively for the analysis (a) of 
the MD trajectory. 
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Table S6: Comparison between the experimentally derived distance restraints (dlow), (dupp) and calculated 
(dMD) interproton distances of compound 10 as obtained from unrestrained MD calculation (r-6 averaged 
distance that were calculated back from 2001 frames of the 100 ns MD trajectory). dMD is equal to rapp in 
equation S1. Violations of upper bounds (positive sign) and of lower bounds within the MD trajectory 
(negative sign) are also given (dviol). 
interproton distance dlow [Å] dupp [Å] dDG [Å] dMD [Å] dviol [Å]
(*) utilization(**) 
NMe-Arg1 Ha NMe-Arg1 HMe 2.45 3.4 2.51 2.50  c 
NMe-Arg1 Ha Gly2 HN 2.49 3.05 2.56 2.21 -0.28 a 
NMe-Arg1 HMe Gly2 HN 3.13 4.23 4.53 3.59  c 
NMe-Arg1 Ha Asp3 HN 4.11 5.03 4.78 5.63 +0.6 c 
NMe-Arg1 Ha Val5 HgproS 5.45 7.06 5.82 6.64  a 
NMe-Arg1 HMe Val5 HN 4.5 8.00 4.52 4.73  c 
NMe-Arg1 HMe Val5 Ha 2.3 3.21 2.50 2.44  c 
NMe-Arg1 HMe Val5 HgproS 4.74 6.6 4.05 5.09  a 
NMe-Arg1 HMe Val5 HgproR 4.23 5.97 5.26 4.27  a 
Gly2 HN Asp3 HN 2.43 2.97 3.18 3.79 +0.82 c 
Gly2 HN NMe-D-Phe4 HMe 3.8 5.04 6.11 5.71 +0.67 c 
Gly2 HN Val5 HN 4.49 5.49 6.00 5.34  c 
Asp3 HN Asp3 Ha 2.88 3.08 2.76 2.70 -0.18 c 
Asp3 Ha NMe-D-Phe4 HMe 2.34 3.26 2.38 2.41  c 
NMe-D-Phe4 HMe NMe-D-Phe4 Ha 3.5 4 3.26 3.57  c 
NMe-D-Phe4 Ha Val5 HN 2.06 2.52 2.21 2.10  c 
NMe-D-Phe4 Ha Val5 HgproS 4.51 5.91 6.04 4.69  a 
NMe-D-Phe4 Ha Val5 HgproR 4.5 5.9 4.57 5.76  a 
NMe-D-Phe4 HMe Val5 HN 3.9 5.16 4.49 4.90  c 
NMe-D-Phe4 HMe Val5 Ha 3.93 5.2 5.59 5.58 +0.38 a 
Val5 HN Val5 Ha 2.88 3.08 2.89 2.80 -0.08 c 
Val5 HN Val5 Hb 3.13 3.83 3.16 2.49 -0.64 c 
Val5 HN Val5 HgproS 2.79 3.81 4.33 3.10  c 
Val5 HN Val5 HgproR 3.65 4.86 2.97 3.82  c 
Val5 Ha Val5 Hb 2.17 2.65 2.28 2.66 +0.01 c 
Val5 Ha Val5 HgproS 3.59 4.78 2.61 2.99 -0.60 c 
Val5 Ha Val5 HgproR 2.75 3.76 3.37 2.90  c 
 
(*) Insufficient sampling of the dynamics (the length of MD simulations is limited), inaccuracy of the force fields and additional J mediated transfer 
within ROESY may explain for violations. 
 (**) Distance information used as restraints within the preceding DG calculation (c) and distance information used exclusively for the analysis (a) of 
the MD trajectory. 
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Table S7: Temperature dependence of HN chemical shifts, 3JHN-Ha coupling constants, 3JHa-Hß coupling 
constants and the according ?1 populations. The ranges given for the ?1 populations were derived by 
assuming the following pairs of coupling constants: 3JHa-Hß(ap) = 12 Hz and 3JHa-Hß(ga) = 3.5 Hz as well as 
3JHa-Hß(ap) = 13.6 Hz, 3JHa-Hß(ga) = 2.6 Hz. 
3JHa-Hß [Hz] 
 ? ? /?T [ppb/K] 
3JHN-Ha 
[Hz]  Ha-Hß proR, Ha-Hß proS 
p(?? = -60°) 
[%] 
p(?? = 180°) 
[%] 
p(?? = 60°) 
[%] 
1      
Arg1 -5.02 7.0 ca. 9 / ca. 6 90-94 6-10 
Gly2 -4.16 7.2 / 2.8    
NMe-Asp3   8.5 / 5.4 83-85 15-17 
D-Phe4 -8.38 9.3 8.8 (R) / 5.8 (S) 10-15 56-63 27-29 
NMe-Val5   11.2 0-22 78-90 0-22 
      
4      
NMe-Arg1   11.2 / 4.8 98-100 0-2 
Gly2 -5.04 5.7 / 5.1    
Asp3 -4.93 9.0 8.4 (R) / 5.7 (S) 26-28 53-58 16-19 
D-Phe4 -2.34 8.2 8.2 (R) / 5.3 (S) 24 51-55 21-25 
NMe-Val5   10.7 0-26 74-85 0-26 
      
10      
NMe-Arg1   9.4 / 4.8 82-85 15-18 
Gly2 -3.05 8.1 / 4.2    
Asp3 - 9.0 10.8 (R) / 3.8 (S) 4-11 74-86 10-15 
NMe-D-
Phe4   8.5 / 7.1 0-5 95-100 
Val5 0.53 8.9 3.3 73 0-6 21-27 
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6. Molecular Modeling. 
Model Building. The multiple sequence alignment suggested in a previous paper was used to build the 
ß5 subuinit by means of homology modeling. The program MODELLER (version 9v8) [20] was 
employed to build one hundred full-atom models of the human ß5 subunit according to the comparative 
protein modeling method. The template used was the X-ray structure of the avß3 integrin in complex 
with the Cilengetide (PDB entry code 1L5G). The human ß3 and ß5 subunits are homolog proteins 
sharing 65% identity in the construct used. The modeling procedure is conceptually similar to that used in 
the determination of protein structures from NMR-derived restraints. The restraints, distances and 
dihedral angles, are extracted from the template structure. Additionally, stereochemical restraints such as 
bond length and bond angle preferences obtained from the molecular mechanics force field of 
CHARMM-22 are used together with statistical preferences of dihedral angles and nonbonded atomic 
distances obtained from a representative set of all known protein structures. The model is then calculated 
through cycles of geometry optimization and molecular dynamics simulation. Fifteen initial models were 
obtained using standard parameters. In a first stage, the best five models were selected on the basis of 
Procheck [21] geometrical quality and DOPE scoring, and these were subjected to geometrical 
improvement by the Molprobity server [22]. In a second stage, the best model from the previous step 
was subjected to loop optimization of the SDL region (residues 185- 215 in ß5) with the LoopModel 
routine in Modeler [23], generating 100 refined models. These models were then ranked using the 
MODELLER objective function, which is highly efficient in ranking different models calculated from the 
same alignment [20] and only the best ones (i.e. the ones having negative scores) were further 
considered. The backbone atoms of the predicted models overlapped well and mainly differed in the 
conformation of the SDL region. 
Docking simulations. Docking of 1, 4 and 10 in the X-ray three-dimensional structure of avß3 (PDB 
code: 1L5G) and in the avß5 homology model, was carried out using the AutoDock 4.2 [24] software 
package as implemented through the graphical user interface AutoDockTools (ADT 1.5.2). The choice 
of this software for docking calculations was suggested by its good performances in the integrin field and 
in perspective studies (i.e. VS experiments) led by us [25-28]. The conformations of peptides 1, 4 and 10 
as experimentally determined by DG, and subsequent molecular dynamics were used as docking starting 
structures. More precisely, for 1 and 4, for which the MD was 50 ns long, one conformation each 1 ns 
was used along with the best conformation resulting from DG calculations. In the case of 10, 50 frames 
were obtained by saving one conformation each 2 ns from the 100 ns MD trajectory together with the 
best DG structure. During the docking process the backbone conformation was held fix, while the side 
chain dihedral angles were free to rotate. The peptides and the receptor structure were converted to AD4 
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format files using ADT generating automatically all other atom values. The docking area has been 
defined by a box, centered on the coordinate of the metal in the MIDAS region. Grid points of 70×82×76 
with 0.375 Å spacing were calculated around the docking area for all the ligand atom types using 
AutoGrid 4.2. For each ligand, 200 separate docking calculations were performed. Each docking 
calculation consisted of 10 million energy evaluations using the Lamarckian genetic algorithm local 
search (GALS) method. A low frequency local search according to the method of Solis and Wets was 
applied to docking trials to ensure that the final solution represents a local minimum. Each docking run 
was performed with a population size of 150, and 300 rounds of Solis and Wets local search were 
applied with a probability of 0.06. A mutation rate of 0.02 and a crossover rate of 0.8 were used to 
generate new docking trials for subsequent generations. The GALS method evaluates a population of 
possible docking solutions and propagates the most successful individuals from each generation into the 
next one. The docking results from each of the 200 calculations were clustered on the basis of root mean 
square deviation (rmsd = 2.0 Å) between the Cartesian coordinates of the ligand atoms and were ranked 
on the basis of the free energy of binding.  
However, for each ligand, the free energy of binding as well as the consonance with experimental data, 
(i.e SARs) were taken into account for the choice of the published binding modes. Specifically, analysis 
of the docking results was attained by retrieving for each peptides conformer the lowest energy binding 
conformation, thus 51 binding poses were considered for 1, 4 and 10. A visual inspection of the results 
demonstrated that a single conformation can: i) reasonably bind only one of the two receptors, ii) 
indiscriminately bind both receptors, iii) poorly bind both receptors (conformations were not able to 
contact both the metal in the MIDAS region and the critical aspartates in the av subunit). Then a 
clustering of all conformers was attained  based on these major behaviors. In the case of 1 it was noticed 
that the majority of the conformers binding one of the two receptors (avb3), in line with experimental 
data, were represented by the DG conformation (see Figure 3a in the main text) and all the MD frames 
similar to the latter. On the contrary, in the case of 4 the frame from DG and the ones from MD were 
able to bind in a similar fashion both the receptor subtypes in line with experimental data (consistently 
with compound 1 the binding pose of the DG conformer was reported in Figure S1). Differently, in none 
of the docked solution obtained for 10 the ligand can efficiently contact the two receptors (see main 
text).   
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7.  Competitive solid-phase integrin binding assay 
The in vitro inhibition of integrin – extracellular matrix protein binding was measured using a solid-phase 
binding assay based on previously reported methods with some modifications [29, 30]. Human integrins 
avb3 and avb5 were purchased from Millipore, a5b1 from R&D Systems and aIIbb3 from Enzyme 
Research Laboratories. Vitronectin was purchased from Millipore, fibronectin from Sigma and fibrinogen 
from Calbiochem. For the integrins a5b1 and aIIbb3 the binding was visualized using antibodies from 
BD Biosciences (mouse anti-human CD49e for a5b1 and mouse anti-human CD41b for aIIbb3) and 
Sigma (anti-mouse IgG-peroxidase). Peroxidase development was performed using the substrate solution 
3,3,5,5’-tetramethylethylenediamine (TMB from Seramun Diagnostic GmbH) and 3 M H2SO4 for 
stopping the reaction. Alternatively, for the integrins avb3 and avb5 the binding was detected using the 
conjugate neutravidin-horseradish peroxidase (HRP) from Pierce and the HRP substrate o-
phenylenediamine hydrochloride (OPD) from Sigma. The absorbance (450, 492 nm) was recorded with a 
POLARstar Galaxy plate reader (BMG Labtechnologies). Every concentration was analyzed by duplicate 
and the resulting inhibition curves were analyzed using OriginPro 7.5G software, the turning point 
describes the IC50 value. Each plate contained Cilengitide or tirofiban as internal control [31]. Blocking 
and binding steps were always performed with TS buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
CaCl2, 1 mM MgCl2, and 1 mM MnCl2) containing 1% BSA (TSB-buffer). Washings after each 
incubation step were done with PBST buffer (10 mM Na2HPO4 pH 7.5, 150 mM NaCl, and 0.01% 
Tween 20).  
Vitronectin-avb3 assay. Flat-bottom 96-well ELISA plates (Brand) were coated overnight at room 
temperature with 100 µL/well of 0.4 µg/mL human avb3 in TS buffer. After emptying the plate the wells 
were blocked for 2 h at 30 °C with 150 µL/well of TSB. Plates were then washed three times with 200 
µL/well of PBST. Next, test compounds and Cilengitide as internal control (0.0003-10 µM) were mixed 
with 1 µg/mL of human vitronectin, which had been biotinylated with sulfo-NHS-LC-LC-biotin (Pierce, 
20:1 molar ratio), and 100 µL/well of these solutions were incubated for 2 h at 30 °C. After washing the 
plates five times, 100 µL/well of 0.25 µg/mL of neutravidin-HRP were added to the plate and incubated 
for 1 h at 30 °C. After another 5-fold wash, the plate was developed by adding 100 µL/well of OPD 
solution, obtained from dissolving substrate tablets in buffer (24 mM sodium citrate, 50 mM Na2HPO4 
pH 5.0, 0.012% H2O2). After 15 min the reaction was quenched with 3 M H2SO4 and the binding 
analyzed at 492 nm as described above. 
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Vitronectin-avb5 assay. The assay is similar to the vitronectin-avb3 assay. In brief, flat-bottom 96-well 
ELISA plates were coated overnight at room temperature with 100 µL/well of 1.0 µg/mL human avb5 in 
TS buffer. After blocking and washing the plates, test compounds and Cilengitide were mixed with 1 
µg/mL of human biotinylated-vitronectin and were incubated for 2 h at 30 °C. The binding was visualized 
by incubation with neutravidin-HRP and further oxidation of the OPD substrate. IC50 values were 
calculated as previously described. 
Fibronectin-a5b1 assay. Flat-bottom 96-well ELISA plates were coated overnight at 4 °C with 100 
µL/well of 0.50 µg/mL of fibronectin in 15 mM of Na2CO3, 35 mM NaHCO3, pH 9.6 (carbonate buffer). 
Plates were subsequently blocked for 1 h at room temperature. Next, 1.0 µg/mL of soluble integrin a5b1 
and a serial dilution of integrin inhibitors and the control Cilengitide were incubated in the coated wells 
for 1 h at room temperature. After washing three times, the plate was treated with 100 µL/well of 
primary antibody (CD49e) at 1.0 µg/mL (1:500 dilution) and secondary antibody (anti-mouse IgG-
peroxidase) at 2.0 µg/mL (1:385 dilution) for 1 h each at room temperature. After this treatment the 
plate was washed three times and the binding visualized with TMB. For this substrate the oxidation was 
left for only 5 min and the absorbance measured at 450 nm. IC50 determination was done as explained 
above.  
Fibrinogen-aIIbb3 assay. The assay is similar to the fibronectin-a5b1 assay. In this case, flat-bottom 
96-well ELISA plates were coated overnight at 4 °C with 100 µL/well of 10.0 µg/mL of fibrinogen in 
carbonate buffer. After blocking the plates, 2.5 µg/mL of soluble integrin aIIbb3 and a serial dilution of 
integrin inhibitors and the control molecules cilengitide and tirofiban were incubated in the coated wells 
for 1 h at room temperature. The plate was then washed three times and subsequently treated with 100 
µL/well of primary antibody (CD41b) at 2.0 µg/mL (1:250 dilution) and secondary antibody (anti-mouse 
IgG-peroxidase) at 1.0 µg/mL (1:770 dilution) for 1 h each at room temperature. The binding was 
visualized as explained for a5b1.  
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Figure S1. Structure of 4 (orange) docked in the avß3 (a) and avß5 (b) integrins. The av, ß3 and ß5 
subunits are represented by pink, cyan and blue surfaces, respectively. In both subunits the amino acid 
side chains important for the ligand binding are represented as sticks. The metal ion in the MIDAS region 
is represented by a magenta sphere.  
 
 
Figure S2. a) X-ray binding conformation of Cilengitide (green sticks) and b) NMR solution structure of 
peptide 10 (orange sticks).  
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